A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
Latest Information Update: 04 Oct 2023
Price :
$35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisolone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACCEPT
- 26 Sep 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results (n=38; From May 2017 to Jan 2020) assessing safety and efficacy of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone in untreated de novo DLBCL, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 26 Oct 2022 Planned End Date changed from 31 Jul 2022 to 31 Jan 2023.